Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2010-11-15 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Lapse of Options 1 page ?Kb
Regulatory Filings Classification · 90% confidence The document is a short announcement to the Australian Stock Exchange regarding the lapse of unlisted options due to expiry. It does not contain financial statements, detailed financial data, or management discussion. It is a regulatory announcement about capital instruments (options) lapsing, which relates to capital structure changes but is more of a notification than a detailed financing update. Given the nature and length of the document, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a detailed Capital/Financing Update (CAP).
2010-11-15 English
Annual General Meeting Presentation 15 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation November 2010' and contains detailed slides about clinical trials, regulatory applications, commercialization strategy, ongoing R&D projects, and quality management systems. The content is consistent with a presentation given at an Annual General Meeting (AGM), focusing on company updates, clinical trial results, and future outlook rather than a formal annual report or financial statements. There is no indication of full financial statements or detailed financial performance data that would classify it as an Annual Report (10-K) or Interim Report (IR). The document is not a transcript, audit report, or regulatory filing. The presence of multiple slides and detailed project updates aligns with an investor or shareholder presentation at an AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (11,684 characters) supports it being a full presentation rather than a brief announcement or notice.
2010-11-09 English
Chairman`s Address to Shareholders 3 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS' and is addressed as an announcement to the Australian Stock Exchange for the Annual General Meeting (AGM) of bioMD Limited. It contains a summary of the company's activities, clinical trials, research, and financial results for the year ended 30 June 2010. The content is typical of a Chairman's speech delivered at an AGM, providing highlights and an overview rather than detailed financial statements or comprehensive annual report data. The document length is 6171 characters, which is consistent with a detailed AGM presentation or address. There is no indication that this is the full Annual Report (10-K) or a financial report, nor is it a simple announcement of a report publication. Therefore, the document best fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting.
2010-11-09 English
Results of Meeting 1 page ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement to the Australian Stock Exchange regarding the results of an Annual General Meeting (AGM) held on 10 November 2009. It details the voting outcomes on resolutions, including the adoption of the remuneration report and re-election of a director. The content focuses on the official results of shareholder votes at the AGM, which matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and does not contain full financial reports or detailed presentations, so it is not an Annual Report or AGM Information. Therefore, the correct classification is DVA with high confidence.
2010-11-09 English
Market Update 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement to the Australian Stock Exchange about achieving a milestone in a tissue heart valve feasibility study. It discusses progress in research and development, potential commercial outcomes, and market information. The document is relatively short (3921 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is not a full financial report, audit, or earnings release. It is also not a notice of voting results, board changes, or legal proceedings. The content is primarily an operational update and milestone achievement announcement related to R&D progress. Given the length and content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2010-10-31 English
Appendix 4C - quarterly 6 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C - Quarterly Report' and is addressed as an announcement to the Australian Stock Exchange. It contains detailed quarterly financial data, specifically a consolidated statement of cash flows for the quarter ended 30 September 2010. The document includes cash flow details related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The presence of actual financial statements and substantive financial data for a quarter indicates this is a comprehensive interim/quarterly financial report. The document length is 7207 characters, which is sufficient to contain detailed financial data rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2011
2010-10-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.